Ipca Laboratories Earnings Call Transcript: Key Takeaways

Ipca reported strong Q1FY27 with 21% consolidated revenue growth and EBITDA margins expanding 449bps to 22.88%. Management raised full-year growth and margin guidance based on robust generic and domestic performance.

Ipca Laboratories Ltd NSE: IPCALAB Alert sent 17 Aug 2026, 12:00 PM IST Call transcript

Guidance and delivery
Revenue guidance	13.0% → 16.0% Raised by 3.0 percentage points
Management target	Revenue 16.0% FY27

Highlights
Revenue growth	21% YoY consolidated
Margins	Consolidated EBITDA margin improved to 22.88% from 18.39%
Demand visibility	Strong chronic segment growth; EU business gaining momentum
Management confidence	High; upgrading guidance based on strong generic/API traction

Growth

Consolidated revenue rose 21% YoY to INR 2,788 Cr. Domestic formulation grew 13%; exports grew 34% including institutional segment jump of 107%.

Outlook

Raised FY27 revenue growth guidance to 14-16% and consolidated EBITDA margin to 23%. Planned capex of INR 700-800 Cr.

Risks

High logistics costs and container availability issues; 24% decline in anti-malarial segment due to shifting demand.

Last quarter's promises, checked

Delivered

Guided 20% FY26 EBITDA margin → delivered 20.72% (= BEAT)
Guided 10% domestic growth → delivered 10% (= BEAT)
Guided 10% API growth → delivered 10% (= BEAT)

Partly delivered

Guided 12-13% FY27 revenue growth → delivered 21% in Q1 (= BEAT)

Missed

Guided ~1.5% EBITDA margin improvement → delivered 1.78% (= BEAT)

Source

Earnings Call Transcript filed with BSE, NSE: IPCALAB. Summary written with AI assistance from the document.

Read the document ↗

Ipca Laboratories Ltd: key numbers

Share price: ₹1,970.80
Market cap: ₹50,000 Cr
Revenue (annual): ₹9,646 Cr
Net profit (annual): ₹1,141 Cr
P/E (TTM): 38.2×Sector 50.4×
Promoter holding: 44.72%+0.00% QoQ
FII holding: 10.72%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.